Continuing Medical Education
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this internet live activity for a maximum of 11.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Tuesday, May 5, 2020. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via the link below and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
The incredible clinical success of immunotherapies, particularly immune checkpoint inhibitors, has resulted in widespread use across many cancers and exploration of use in autoimmune and rheumatic diseases. As utilization has increased, so too have observations and reports of toxicities, sometimes severe, in nearly every organ system. These immune-related adverse events (irAEs) manifest differently depending on the pathway targeted by the therapy (i.e., CTLA-4 or PD-1/PD-L1), and the emerging use of combination therapies has only increased the frequency of events.
In order to better understand, predict, and treat immunotoxicities in cancer patients, clinicians need to first understand the mechanisms underlying irAEs. Recognizing the similarities to and associations with autoimmune diseases—which share many biological underpinnings with irAEs—will also be beneficial, as will increased awareness of how irAEs present across multiple organ systems.
The NIH-AACR Cancer, Autoimmunity, and Immunology Conference will bring together world-renowned oncologists, immunologists, rheumatologists, and basic researchers to address these gaps. Attendees will hear about cutting-edge research on the role of the microbiome in determining response to immunotherapies; biomarkers for predicting irAEs; and irAEs resulting from combination therapies. They will learn how nontraditional nonclinical models are being used to interrogate response to treatment and the mechanistic bases for irAEs. There will be sessions dedicated to rheumatic toxicities and to multidisciplinary treatment models. Important considerations, such as biomarker validation and differentiation of adverse events from checkpoint inhibitors and traditional therapies when used in combination, will be discussed.
After participating in this CME activity, physicians should be able to:
- Articulate influences and effects of the gut microbiome on patients’ response to immunotherapy.
- Integrate multidisciplinary treatment strategies into patient care.
- Identify multiple biomarkers for predicting development of irAEs.
- Extrapolate the relevance of research and clinical findings on irAEs to the study and treatment of rheumatic and autoimmune diseases, and vice versa.
- Explain how more relevant nonclinical models are being developed and used to investigate mechanisms underlying irAEs following immunotherapy.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conferenceand website of this conference. The disclosure information is available here.
Acknowledgment of Financial or Other Support
This activity may be supported by Professional Educational Grants from AstraZeneca and Merck.